Evaluation and treatment of medication-overuse headache: Russian experts’ guidelines
G. R. Tabeeva,
V. V. Osipova,
E. G. Filatova,
Yu. E. Azimova,
A. V. Amelin,
A. R. Artyomenko,
Yu. D. Vorobyeva,
E. V. Ekusheva,
M. I. Koreshkina,
E. R. Lebedeva,
N. V. Latysheva,
M. V. Naprienko,
A. V. Sergeev,
K. V. Skorobogatykh,
V. A. Golovacheva,
A. P. Rachin,
V. A. Parfenov https://doi.org/10.14412/2074-2711-2022-1-4-13
Abstract
The Russian experts’ guidelines on evaluation and treatment of medication-overuse headache are based on evidence-based medicine, the latest revision of the International Classification of Headache Disorders. Basic information about epidemiology, risk factors, pathophysiological mechanisms, evaluation, and the most effective pharmacological drug and non-pharmacological approaches to managing patients with medication-overuse headache are presented.
About the Authors
G. R. Tabeeva
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991
V. V. Osipova
Research and Practical Psychoneurology Center, Moscow Healthcare Department
Russian Federation
Russian Federation
43, Donskaya St., Moscow 115419
E. G. Filatova
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991
Yu. E. Azimova
OOO «University Headache Clinic»;
Research Institute of General Pathology and Pathophysiology
Russian Federation
Russian Federation
2, Molodogvardeiskaya St., Build. 1, Moscow 121467;
8, Baltiyskaya St., Moscow 125315
A. V. Amelin
I.P. Pavlov First Saint Petersburg State Medical University, Ministry of Health of Russia
Russian Federation
Russian Federation
6–8, Lev Tolstoy St., Saint Petersburg 197022
A. R. Artyomenko
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991
Yu. D. Vorobyeva
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991
E. V. Ekusheva
Academy of Postgraduate Education, Federal Scientific and Clinical Center for Specialized Types of Medical Aid and Medical Technologies, FMBA of Russia;
Belgorod State National Research University;
Acad. A. Vein Clinic of Headache and Autonomic Disorders;
OOO “GUTA CLINIC”
Russian Federation
Russian Federation
91, Volokolamskoe Shosse, Moscow 125371;
85, Pobedy St., Belgorod 308015;
10B, Staropetrovskiy proezd, Moscow 125130;
4a, Fadeeva St., Build. 1, Moscow 127006
M. I. Koreshkina
Clinic “Medical Board”
Russian Federation
Russian Federation
1, Michurinskaya St., Saint Petersburg 197046
E. R. Lebedeva
Ural State Medical University, Ministry of Health of Russia;
International Headache Treatment Center “Europe-Asia”
Russian Federation
Russian Federation
3, Repin St., Yekaterinburg 620028;
67, Furmanova St., Yekaterinburg 620144
N. V. Latysheva
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991
M. V. Naprienko
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991
A. V. Sergeev
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991
K. V. Skorobogatykh
OOO «University Headache Clinic»
Russian Federation
Russian Federation
2, Molodogvardeiskaya St., Build. 1, Moscow 121467
V. A. Golovacheva
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991
A. P. Rachin
National Medical Research Center for Rehabilitation and Balneology, Ministry of Health of Russia
Russian Federation
Russian Federation
32, Novyi Arbat St., Moscow 121099
V. A. Parfenov
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
Russian Federation
Russian Federation
8, Trubetskaya St., Build. 2, Moscow 119991
References
1. Diener HC, Holle D, Solbach K, Gaul C. Medication-overuse headache: risk factors, pathophysiology and management. Nat Rev Neurol. 2016 Oct;12(10):575-83. doi: 10.1038/nrneurol.2016.124. Epub 2016 Sep 12.
2. Evers S, Marziniak M. Clinical features, pathophysiology, and treatment of medicationoveruse headache. Lancet Neurol. 2010 Apr;9(4):391-401. doi: 10.1016/S1474-4422(10)70008-9
3. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders ICHD-3, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202
4. Westergaard ML, Hansen EH, Glümer C, et al. Definitions of medication-overuse headache in population-based studies and their implications on prevalence estimates: a systematic review. Cephalalgia. 2014;34(6):409-25. doi: 10.1177/0333102413512033
5. Aaseth K, Grande RB, Kvaerner KJ, et al. Prevalence of secondary chronic headaches in a population-based sample of 30–44-yearold persons. The Akershus study of chronic headache. Cephalalgia. 2008 Jul;28(7):705-13. doi: 10.1111/j.1468-2982.2008.01577.x. Epub 2008 May 21.
6. Jonsson P, Hedenrud T, Linde M. Epidemiology of medication overuse headache in the general Swedish population. Cephalalgia. 2011 Jul;31(9):1015-22. doi: 10.1177/0333102411410082. Epub 2011 May 31.
7. Straube A, Pfaffenrath V, Ladwig KH, et al. Prevalence of chronic migraine and medication overuse headache in Germany – the German DMKG headache study. Cephalalgia. 2010 Feb;30(2):207-13. doi: 10.1111/j.1468-2982.2009.01906.x
8. Ayzenberg I, Katsarava Z, Sborowski A, et al; Lifting the Burden. The prevalence of primary headache disorders in Russia: a countrywide survey. Cephalalgia. 2012 Apr;32(5):373-81. doi: 10.1177/0333102412438977
9. Vandenbussche N, Laterza D, Lisicki M, et al. Medication-overuse headache: a widely recognized entity amidst ongoing debate. J Headache Pain. 2018 Jul 13;19(1):50. doi: 10.1186/s10194-018-0875-x
10. Dyb G, Holmen T, Zwart J. Analgesic overuse among adolescents with headache: The HeadHunt-Youth Study. Neurology. 2006 Jan 24;66(2):198-201. doi: 10.1212/01.wnl.0000193630.03650.19
11. Lipton RB, Manack A, Ricci JA, et al. Prevalence and burden of chronic migraine in adolescents: results of the chronic daily headache in adolescents study (C-dAS). Headache. 2011 May;51(5):693-706. doi: 10.1111/j.1526-4610.2011.01885.x
12. Wiendels NJ, van der Geest MC, Neven AK, et al. Chronic daily headache in children and adolescents. Headache. 2005 Jun;45(6):678-83. doi: 10.1111/j.1526-4610.2005.05137.x
13. De Rijk P, Resseguier N, Donnet A. Headache characteristics and clinical features of elderly migraine patients. Headache. 2018 Apr;58(4):525-33. doi: 10.1111/head.13247. Epub 2017 Dec 13.
14. Diener HC, Limmroth V. Medication-overused headache: a worldwide problem. Lancet Neurol. 2004 Aug;3(8):475-83. doi: 10.1016/S1474-4422(04)00824-5
15. Colas R, Munoz P, Temprano R, et al. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology. 2004 Apr 27;62(8):1338-42. doi: 10.1212/01.wnl.0000120545.45443.93
16. Meskunas CA, Tepper SJ, Rapoport AM, et al. Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache. 2006 May;46(5):766-72. doi: 10.1111/j.1526-4610.2006.00442.x
17. Find NL, Terlizzi R, Munksgaard SB, et al; COMOESTAS Consortium. Medication overuse headache in Europe and Latin America: general demographic and clinical characteristics, referral pathways and national distribution of painkillers in a descriptive, multinational, multicenter study. J Headache Pain. 2015;17:20. doi: 10.1186/s10194-016-0612-2. Epub 2016 Mar 8.
18. Paemeleire K, Bahra A, Evers S, et al. Medication-overuse headache in patients with cluster headache. Neurology. 2006;67(1):109-13 doi: 10.1007/s11916-008-0023-4
19. Robbins MS, Grosberg BM, Napchan U, et al. Clinical and prognostic subforms of new daily-persistent headache. Neurology. 2010 Apr 27;74(17):1358-64. doi: 10.1212/WNL.0b013e3181dad5de
20. Baandrup L, Jensen R. Chronic post-traumatic headache – a clinical analysis in relation to the International Headache Classification. Cephalalgia. 2005 Feb;25(2):132-8. doi: 10.1111/j.1468-2982.2004.00818.x
21. Russell MB, Lundqvist C. Prevention and management of medication overuse headache. Curr Opin Neurol. 2012 Jun;25(3):290-5. doi: 10.1097/WCO.0b013e328352c431
22. Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2012 May;19(5):703-11. doi: 10.1111/j.1468-1331.2011.03612.x. Epub 2011 Dec 5.
23. Bendtsen L, Munksgaard S, Tassorelli C, et al; COMOESTAS Consortium. Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia. 2014 May;34(6):426-33. doi: 10.1177/0333102413515338. Epub 2013 Dec 9.
24. Schwedt TJ, Hentz JG, Sahai-Srivastava S, et al; MOTS Investigators. Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial. Headache. 2021 Feb;61(2):351-62. doi: 10.1111/head.14056. Epub 2021 Jan 12.
25. Schwedt TJ, Buse DC, Argoff CE, et al. Medication Overuse and Headache Burden Results From the CaMEO Study. Neurol Clin Pract. 2021 Jun;11(3):216-26. doi: 10.1212/CPJ.0000000000001037
26. Tassorelli C, Jensen R, Allena M, et al. The added value of an electronic monitoring and alerting system in the management of medication-overuse headache: A controlled multicentre study. Cephalalgia. 2017 Oct;37(12):1115-25. doi: 10.1177/0333102416660549. Epub 2016 Jul 20.
27. Katsarava Z, Jensen R. Medication-overuse headache: where are we now? Curr Opin Neurol. 2007 Jun;20(3):326-30. doi: 10.1097/WCO.0b013e328136c21c
28. Diener HC, Antonaci F, Braschinsky M, et al. European Academy of Neurology guideline on the management of medication-overuse headache. Eur J Neurol. 2020 Jul;27(7):1102- 16. doi: 10.1111/ene.14268. Epub 2020 May 19.
29. Sergeyev AV, Meshcherina MI, Tabeyeva GR. Headache associated with excessive usage of analgesics: clinical-psychological and neurophysiological analysis, and specifics of the period of the period of drug withdrawal. Epilepsiya i paroksizmal'nyye sostoyaniya. 2011;3(3):21-8 (In Russ.).
30. Istomina OI, Filatova EG. Medication overuse headache: sociodemographic and clinical analyses. Vrach. 2011;(1):68-71 (In Russ.)
31. Tassorelli C, Jensen R, Allena M, et al. A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia. 2014 Aug;34(9):645-55. doi: 10.1177/0333102414521508. Epub 2014 Feb 20.
32. Kristoffersen ES, Lundqvist C. Medicationoveruse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014 Apr;5(2):87-99. doi: 10.1177/2042098614522683
33. Osipova V, Jensen R, Tassorelli C. The use of diaries in the management of headache. In: Martelletti P, Steiner TJ, editors. Handbook of Headache (Practical Management). 2011. Vol. 4. P. 197-209. doi: 10.1007/978-88-470-1700-9_13
34. Mitsikostas DD, Ashina M, Craven A, et al & EHF Committee. European Headache Federation consensus on technical investigation for primary headache disorders. J Headache Pain. 2015;17:5. doi: 10.1186/s10194-016-0596- y. Epub 2016 Feb 9.
35. Practice parameter: the utility of neuroimaging in the evaluation of headache in patients with normal neurologic examinations (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 1994 Jul;44(7):1353-4. doi: 10.1212/wnl.44.7.1353
36. Osipova VV, Skorobogatykh KV, Artemenko AR, Sergeev AV. Severe druginduced headache with its possible recurrent statuses in a patient with chronic tension headache. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):73-8. doi: 10.14412/2074-2711-2020-4-73-78 (In Russ.).
37. Filatova EG, Osipova VV, Tabeeva GR, et al. Diagnosis and treatment of migraine: Russian experts' recommendations. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2020;12(4):4- 14. doi: 10.14412/2074-2711-2020-4-4-14 (In Russ.).
38. Schwedt TJ, Alam A, Reed ML, et al. Factors associated with acute medication overuse in people with migraine: results from the 2017 migraine in America symptoms and treatment (MAST) study. J Headache Pain. 2018 May 24;19(1):38. doi: 10.1186/s10194-018-0865-z
39. Cevoli S, Sancisi E, Grimaldi D, et al. Family history for chronic headache and drug overuse as a risk factor for headache chronification. Headache. 2009 Mar;49(3):412-8. doi: 10.1111/j.1526-4610.2008.01257.x
40. Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre-clinical characteristics and treatment outcomes. Cephalalgia. 2004 Jun;24(6):483-90. doi: 10.1111/j.1468-2982.2004.00691.x
41. Meng ID, Dodick D, Ossipov MH, Porreca F. Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies. Cephalalgia. 2011 May;31(7):851-60. doi: 10.1177/0333102411402367. Epub 2011 Mar 28.
42. Calabresi P, Cupini L. Medication-overuse headache: similarities with drug addiction. Trends Pharmacol Sci. 2005 Feb;26(2):62-8. doi: 10.1016/j.tips.2004.12.008
43. Srikiatkhachorn A, Anthony M. Serotonin receptor adaptation in patients with analgesicinduced headache. Cephalalgia. 1996 Oct;16(6):419-22. doi: 10.1046/j.1468-2982.1996.1606419.x
44. Kondratieva N, Azimova J, Skorobogatykh K, et al. Biomarkers of migraine: Part 1 – Genetic markers. J Neurol Sci. 2016 Oct 15;369:63-76. doi: 10.1016/j.jns.2016.08.008. Epub 2016 Aug 3.
45. Bongsebandhu-Phubhakdi S, Srikiatkhachorn A. Pathophysiology of medication-overuse headache: implications from animal studies. Curr Pain Headache Rep. 2012 Feb;16(1):110-5. doi: 10.1007/s11916-011- 0234-y
46. Munksgaard S, Ertsey C, Frandsen E, et al. Circulating nociceptin and CGRP in medication-overuse headache. Acta Neurol Scand. 2019 Mar;139(3):269-75. doi: 10.1111/ane.13053. Epub 2018 Dec 11.
47. Riederer F, Schaer M, Gantenbein AR, et al. Cortical Alterations in MedicationOveruse Headache. Headache. 2017 Feb;57(2):255-65. doi: 10.1111/head.12993. Epub 2016 Dec 28.
48. Diener HC, Dodick D, Evers S, et al. Pathophysiology, prevention, and treatment of medication overuse headache. Lancet Neurol. 2019 Sep;18(9):891-902. doi: 10.1016/S1474-4422(19)30146-2. Epub 2019 Jun 4.
49. Carlsen LN, Westergaard ML, Bisgaard M, et al. National awareness campaign to prevent medication-overuse headache in Denmark. Cephalalgia. 2018 Jun;38(7):1316-25. doi: 10.1177/0333102417736898. Epub 2017 Oct 10.
50. Shagbazyan AE, Kovalchuk NA, Tabeeva GR. Role of educational programs in management of patients with medicationoveruse headache. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(3):27-33. doi: 10.14412/2074-2711-2021-3-27-33 (In Russ.).
51. Danilov AB, Shevchenko EV. Impact of patient information-educational preparation on clinical, financial, and economic factors and treatment satisfaction. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2014;(2):29- 33. doi: 10.14412/2074-2711-2014-2-29-33 (In Russ.).
52. Kristoffersen ES, Straand J, Russell MB, Lundqvist C. Lasting improvement of medication-overuse headache after brief intervention – a long-term follow-up in primary care. Eur J Neurol. 2017 Jul;24(7):883-91. doi: 10.1111/ene.13318. Epub 2017 May 23.
53. Zeeberg P, Olesen J, Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia. 2006 Oct;26(10):1192-8. doi: 10.1111/j.1468-2982.2006.01190.x
54. Carlsen LN, Munksgaard SB, Jensen RH, Bendtsen L. Complete detoxification is the most effective treatment of medication-overuse headache: a randomized controlled open-label trial. Cephalalgia 2018;38:225-36. doi: 10.1177/0333102417737779
55. Tepper SJ, Diener HC, Ashina M, et al. Erenumab in chronic migraine with medication overuse: Subgroup analysis of a randomized trial. Neurology. 2019 May 14;92(20):e2309- e2320. doi: 10.1212/WNL.0000000000007497
56. De Goffau MJ, Klaver ARE, Willemsen MG, et al. The Effectiveness of Treatments for Patients with Medication Overuse Headache: A Systematic Review and Meta-Analysis. J Pain. 2017 Jun;18(6):615- 27. doi: 10.1016/j.jpain.2016.12.005
57. Sergeev AV, Parfenov VA. Medication overuse headache: Practical guidelines. Meditsinskiy sovet = Medical Council. 2018;(1):26-32. doi: 10.21518/2079-701X-2018-1-26-32 (In Russ.)].
58. Chiang CC, Schwedt TJ, Wang SJ, Dodick DW. Treatment of medication-overuse headache: a systematic review. Cephalalgia. 2016 Apr;36(4):371-86. doi: 10.1177/0333102415593088. Epub 2015 Jun 29.
59. Rossi P, Di Lorenzo C, Faroni J. Advice alone vs. structured detoxification programmes for medication overuse headache: a prospective, randomized trial in transformed migraine patients with low medical needs. Cephalalgia. 2006;26(9):1097-105. doi: 10.1111/j.1468-2982.2006.01175.x
60. Toom K, Braschinsky M, Obermann M, Katsarava Z. Secondary headache attributed to exposure to or overuse of a substance. Cephalalgia. 2021 Apr;41(4):443-52. doi: 10.1177/0333102420942238
61. Silberstein SD, Lipton RB, Dodick DW, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007 Feb;47(2):170-80. doi: 10.1111/j.1526-4610.2006.00684.x
62. Negro A, Curto M, Lionetto L, Martelletti P. A two years open-label prospective study of OnabotulinumtoxinA. 195 U in medication overuse headache: a real-world experience. J Headache Pain. 2015;17:1. doi: 10.1186/s10194-016-0591-3. Epub 2016 Jan 21.
63. Pazdera L, Ning X, Campos VR, et al. Efficacy of fremanezumab in patients with migraine and documented inadequate response to 3 or 4 migraine preventive medication classes and medication overuse in the international, multicenter, randomized placebo-controlled FOCUS study. Poster, 14th European Headache Federation Congress, 2020. doi: 10.1186/s10194-021-01232-8
64. Raggi A, Giovannetti AM, Leonardi M, et al. Predictors of 12-Months Relapse After Withdrawal Treatment in Hospitalized Patients With Chronic Migraine Associated With Medication Overuse: A Longitudinal Observational Study. Headache. 2017 Jan;57(1):60-70. doi: 10.1111/head.12979
65. Zidverc-Trajkovic JJ, Pekmezovic T, Jovanovic Z, et al. Long-term predictors of remission in patients treated for medication-overuse headache at a specialized headache center: A prospective cohort study. Cephalalgia. 2018 Feb;38(2):265-73. doi: 10.1177/0333102416683918
Review
For citations:
Tabeeva GR, Osipova VV, Filatova EG, Azimova YE, Amelin AV, Artyomenko AR, Vorobyeva YD, Ekusheva EV, Koreshkina MI, Lebedeva ER, Latysheva NV, Naprienko MV, Sergeev AV, Skorobogatykh KV, Golovacheva VA, Rachin AP, Parfenov VA. Evaluation and treatment of medication-overuse headache: Russian experts’ guidelines. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2022;14(1):4-13. (In Russ.) https://doi.org/10.14412/2074-2711-2022-1-4-13
Views:
924
Email this article 